Optalysys Ltd. Expands Into Chinese Market

Light-Speed Optical Computing Startup demonstrates prototype technology for high performance genetic sequence alignment at ICG-12 Conference, Shenzhen China

GLASSHOUGHTON, WEST YORKSHIRE, U.K. and RENO, Nev. U.S.–October 26, 2017—Optalysys Ltd. (@Optalysys), a start-up pioneering optical computing solutions to address the world’s biggest challenges, at the speed of light, today announced its commitment to the Chinese Life Sciences market.  Optalysys is demonstrating its the latest prototype of its breakthrough technology for genomic searching at the 12th International Conference for Genomics (ICG-12) in Shenzhen, China on 26-28th October 2017.

“The global demand for faster processing of ever expanding volumes of data is outpacing the capabilities of computing, particularly in the burgeoning areas of Deep Learning, Scientific Simulation and Big Data analysis.” said Dr. Nick New, CEO of Optalysys. “Power consumption is also now a major constraint in running high performance computing tasks.  Optalysys optical processing solutions are highly scalable and complement existing computing architectures at a fraction of the energy consumption with the ability to handle massive amounts of data.”

Optalysys first product will perform light speed genetic sequence alignment.  The technology employs a novel correlation-based approach to the task of aligning sequenced reads to a reference sequence. Early tests indicate the technology is capable of a high sensitivity of alignments.  Furthermore the technology allows multiple read sizes to be used, from standard lengths up to next generation read length sizes of thousands of bases.

Genomic alignment is the first of many application areas being targeted by Optalysys. The company  envisions the technology being integrated with standard computer systems across a range of demanding industrial and scientific areas that are becoming limited by the slow-down of progression in electronic computing. “Chinese Life Sciences organisations are global leaders in groundbreaking genomic research and are a top priority focus as potential customers for our first product.” said Emma Blaylock, director, chief commercial officer at Optalysys.